These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33477279)

  • 1. Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.
    Yano S; Tazawa H; Kishimoto H; Kagawa S; Fujiwara T; Hoffman RM
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus.
    Uotani K; Tazawa H; Hasei J; Fujiwara T; Yoshida A; Yamakawa Y; Omori T; Sugiu K; Komatsubara T; Kondo H; Morita T; Kiyono M; Yokoo S; Hata T; Kunisada T; Takeda K; Urata Y; Fujiwara T; Ozaki T
    PLoS One; 2024; 19(2):e0298292. PubMed ID: 38377118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
    Fujiwara T; Tanaka N
    Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
    Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
    Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
    Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
    Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Tanaka N
    Uirusu; 2008 Jun; 58(1):11-8. PubMed ID: 19122384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oncolytic virotherapy for human solid tumors].
    Fujiwara T
    Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy.
    Tazawa H; Hasei J; Yano S; Kagawa S; Ozaki T; Fujiwara T
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S/G2/M phases.
    Yano S; Tazawa H; Hashimoto Y; Shirakawa Y; Kuroda S; Nishizaki M; Kishimoto H; Uno F; Nagasaka T; Urata Y; Kagawa S; Hoffman RM; Fujiwara T
    Clin Cancer Res; 2013 Dec; 19(23):6495-505. PubMed ID: 24081978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase-specific virotheranostics for human head and neck cancer.
    Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
    Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery.
    Kuroda S; Fujiwara T; Shirakawa Y; Yamasaki Y; Yano S; Uno F; Tazawa H; Hashimoto Y; Watanabe Y; Noma K; Urata Y; Kagawa S; Fujiwara T
    Cancer Res; 2010 Nov; 70(22):9339-48. PubMed ID: 21045143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.
    Fujiwara T; Urata Y; Tanaka N
    Front Biosci; 2008 Jan; 13():1881-6. PubMed ID: 17981675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Urata Y; Tanaka N
    Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer.
    Fujiwara T; Kagawa S; Tazawa H
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1809-16. PubMed ID: 21740362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting tumors with a killer-reporter adenovirus for curative fluorescence-guided surgery of soft-tissue sarcoma.
    Yano S; Miwa S; Kishimoto H; Uehara F; Tazawa H; Toneri M; Hiroshima Y; Yamamoto M; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
    Oncotarget; 2015 May; 6(15):13133-48. PubMed ID: 26033451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.